Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by sorafenib (BAY43-9006)
about
Disruptive environmental chemicals and cellular mechanisms that confer resistance to cell deathNovel small molecule Raf kinase inhibitors for targeted cancer therapeuticsGrowth inhibition of human gastric adenocarcinoma cells in vitro by STO-609 is independent of calcium/calmodulin-dependent protein kinase kinase-beta and adenosine monophosphate-activated protein kinaseExpression of drug targets in patients treated with sorafenib, carboplatin and paclitaxelAnti-cancer activity of an osthole derivative, NBM-T-BMX-OS01: targeting vascular endothelial growth factor receptor signaling and angiogenesisFine-tuning vascular fate during endothelial-mesenchymal transition.Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial.RAIN-Droplet: a novel 3D in vitro angiogenesis modelEmerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer.Erk1 and Erk2 regulate endothelial cell proliferation and migration during mouse embryonic angiogenesis.Inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin in an orthotopic model of anaplastic thyroid carcinoma.Personalising and targeting antiangiogenic resistance: a complex and multifactorial approach.Activated STAT3 is a mediator and biomarker of VEGF endothelial activationTie2 in tumor endothelial signaling and survival: implications for antiangiogenic therapy.Tumorigenesis of papillary thyroid cancer is not BRAF-dependent in patients with acromegaly.A novel action mechanism for MPT0G013, a derivative of arylsulfonamide, inhibits tumor angiogenesis through up-regulation of TIMP3 expressionExpression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib.Targeted apoptotic effects of thymoquinone and tamoxifen on XIAP mediated Akt regulation in breast cancerMultiple mechanisms mediate resistance to sorafenib in urothelial cancer5-Formylhonokiol exerts anti-angiogenesis activity via inactivating the ERK signaling pathway.Concurrent versus sequential sorafenib therapy in combination with radiation for hepatocellular carcinoma.Brazilian Propolis Suppresses Angiogenesis by Inducing Apoptosis in Tube-Forming Endothelial Cells through Inactivation of Survival Signal ERK1/2.An active learning approach for rapid characterization of endothelial cells in human tumorsBiomarkers as key contributors in treating malignant melanoma metastases.Early decline in serum phospho-CSE1L levels in vemurafenib/sunitinib-treated melanoma and sorafenib/lapatinib-treated colorectal tumor xenografts.Overexpression of miRNA-497 inhibits tumor angiogenesis by targeting VEGFR2.A novel synthetic small molecule YF-452 inhibits tumor growth through antiangiogenesis by suppressing VEGF receptor 2 signaling.Fisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cellsEpidermal growth factor receptor inhibitors and antiangiogenic agents for the treatment of non-small cell lung cancer.Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertensionA novel polysaccharide from Sargassum integerrimum induces apoptosis in A549 cells and prevents angiogensis in vitro and in vivoThymoquinone inhibits tumor angiogenesis and tumor growth through suppressing AKT and extracellular signal-regulated kinase signaling pathways.Selective Raf inhibition in cancer therapy.Transformed MDCK cells secrete elevated MMP1 that generates LAMA5 fragments promoting endothelial cell angiogenesis.BRAF kinase in melanoma development and progression.Phase II trial of sorafenib in advanced thyroid cancer.Morelloflavone, a biflavonoid, inhibits tumor angiogenesis by targeting rho GTPases and extracellular signal-regulated kinase signaling pathways.Trans-3,4,5,4'-tetramethoxystilbene, a resveratrol analog, potently inhibits angiogenesis in vitro and in vivoMatrix metalloproteinase-activated anthrax lethal toxin inhibits endothelial invasion and neovasculature formation during in vitro morphogenesis.Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program
P2860
Q28080874-CE6CE134-FAE8-4723-92ED-91BDF264020CQ28265862-6693C894-9753-45B3-96BE-360CB5F33E59Q28393172-3734A5CF-A242-4675-9CC2-513E4BC6657BQ28535159-A15C562C-E90F-42CA-BC0B-B5C9F6892E0DQ28535457-7368D9D8-FC08-46B5-B4C7-7B9DEA6D4ED8Q30275793-A40726E3-05F2-401C-82EE-23723AEECD08Q30429122-C5FE6506-3E76-419C-8846-6CA6A1D40FEAQ30579854-467283D8-56B8-4987-AF3A-8ADA0272D350Q33429478-3790149D-A025-499A-BC8D-F63ED3EB9203Q33518538-3EBC06EB-8A91-446C-9822-F936F65974AFQ33590611-0ADE1710-DB9D-46EC-83B4-D6FAEF0C2F94Q33639714-A72040F3-D4D7-4938-BC90-5ED24B351D00Q34099797-379ACC2D-558C-4D6B-8467-357DC5AF8E37Q34116086-6D2DBF66-D5B5-4CBD-A8DE-91DB2A68D34BQ34362091-FEEE1DA9-5739-40CF-895C-EDA0A39856A1Q34654695-D0C11798-0A13-48B0-8E1A-6AA8DEB9AEF4Q34678882-3644761C-B263-47A7-8D9F-869ACF1E6FA1Q34684291-39E8D086-529C-47B8-BE88-57C9A9969E0AQ34685436-4AA6CABE-4C3A-43AB-B69E-45BD58AD9245Q34745159-32F28317-20B8-4720-9AFE-FBE83354D8FDQ34770140-ED4719EA-121D-43DF-ACB6-80E5C8E77572Q35109424-980A884B-70D0-40C1-BA6C-BADFF39D0DD3Q35113340-EADE4A04-A8A3-4B27-BE45-19066368DB5CQ35550888-B14AF1B3-1B7C-4C4E-BA34-A3760728B33AQ35743289-22F01FC7-A6A9-4C72-A579-77B01A0DA7DFQ36033915-81D3730D-9D1D-4023-A2D6-E113482B9360Q36279494-A2A7FDF1-AFB3-4831-BD64-221205B97B89Q36414039-5CA8DF99-E6ED-4AED-96BC-1A314BE845A5Q36482542-A6394FC7-DA73-41C4-8EAE-74AB1CF4FD20Q36739882-ADECED17-B054-4245-A197-1B05CFCDB6F3Q36928661-31A30467-1EE8-49C0-9547-56CAA20856EDQ36983306-37B59FD0-84AD-491C-A976-9A9452DC7305Q37004743-4B119BAF-018C-41EE-AAE0-1214E18B9BC6Q37024034-7D4F679B-C1A3-4ACA-BD4D-1A457052146DQ37086193-5449E8DD-AC25-4040-8EB5-434D565DBE75Q37121708-0AFDDE15-7FFF-427B-8200-D4578898D906Q37142916-DB662DDC-FC2A-461A-B76A-82C359C8CD60Q37150227-1E19F58D-D72A-4105-8B85-C352F778624BQ37178467-CDD6DF49-2E71-46DC-9B57-9A26793C811EQ37295112-0C409C83-8BB2-42A2-B2D4-4DC45F8053D6
P2860
Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by sorafenib (BAY43-9006)
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Inhibition of tumor endothelia ...... owth by sorafenib (BAY43-9006)
@ast
Inhibition of tumor endothelia ...... owth by sorafenib (BAY43-9006)
@en
type
label
Inhibition of tumor endothelia ...... owth by sorafenib (BAY43-9006)
@ast
Inhibition of tumor endothelia ...... owth by sorafenib (BAY43-9006)
@en
prefLabel
Inhibition of tumor endothelia ...... owth by sorafenib (BAY43-9006)
@ast
Inhibition of tumor endothelia ...... owth by sorafenib (BAY43-9006)
@en
P2093
P2860
P1476
Inhibition of tumor endothelia ...... owth by sorafenib (BAY43-9006)
@en
P2093
Christopher Carter
Danielle A Murphy
Michael D Feldman
Sosina Makonnen
Wiem Lassoued
William M F Lee
P2860
P304
P356
10.2353/AJPATH.2006.050711
P407
P577
2006-11-01T00:00:00Z